BC-LI-0186

BC-LI-0186 is a small molecule inhibitor that specifically targets the interaction between leucyl-tRNA synthetase (LRS) and the RagD GTPase. Unlike traditional LRS inhibitors that target the catalytic aminoacylation site, BC-LI-0186 blocks the non-canonical role of LRS as a leucine sensor for the mammalian target of rapamycin complex 1 (mTORC1) pathway. By preventing the LRS-RagD interaction, the drug suppresses hyperactivated mTORC1 signaling and restores autophagy, a critical cellular recycling process. This mechanism is being investigated for the treatment of Duchenne muscular dystrophy (DMD), where dystrophin deficiency leads to LRS-mediated mTORC1 overactivation and subsequent autophagy impairment. Preclinical studies in mdx mice have demonstrated that BC-LI-0186 can restore muscle strength and reactivate autophagy, suggesting it as a potential therapeutic candidate for DMD and other conditions characterized by mTORC1 dysregulation.